Drug Search Results
More Filters [+]

J2H-1702

Alternative Names: J2H-1702, J2H 1702, J2H1702
Latest Update: 2024-03-07
Latest Update Note: Clinical Trial Update

Product Description

J2H-1702 is a novel 11β-HSD1 inhibitor, and the inhibition of 11β-HSD1 has been shown to improve insulin sensitivity, reduce inflammation, and prevent the development of nonalcoholic steatohepatitis (NASH) in preclinical models. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/37743843/)

Mechanisms of Action: 11b-HSD Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: J2H Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for J2H-1702

Countries in Clinic: Korea

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JH-221-201

P2

Recruiting

Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic

2025-01-01

Recent News Events